Skip to main navigation
Skip to search
Skip to main content
Sort by
Immunology and Microbiology
T Cell
100%
Cancer Cell
64%
CD47
53%
Cancer Immunotherapy
34%
CD20
32%
B Cell
32%
Phagocytosis
30%
Bispecific Antibody
28%
Macrophage
26%
TNF related apoptosis inducing ligand
26%
T Cell Receptor
25%
Ecalectin
25%
Monospecific Antibody
25%
Rituximab
23%
Tumor Necrosis Factor
22%
Cell Surface
21%
Antineoplastic Activity
21%
Cell Death
20%
Immune Response
18%
Cytotoxicity
18%
Cytotoxic T-Cell
17%
Inflammatory Arthritis
16%
Granulocyte
16%
Myeloid
15%
Immunotherapy
15%
Tumor Cell
15%
Calreticulin
15%
Neutrophil
14%
Autoimmunity
14%
Tumor Necrosis Factor Receptor
12%
Programmed Death-Ligand 1
12%
Agonist
12%
CD8
11%
Tumor-Infiltrating Lymphocytes
11%
Antigen Specificity
11%
Cell Phagocytosis
11%
CXCL16
10%
Atezolizumab
10%
Isoetarine
10%
Cetuximab
9%
Neutrophil Granulocyte
9%
Lymphocyte
9%
Epidermal Growth Factor
9%
Tumor Immunity
9%
Cell Line
8%
CD40 Ligand
8%
Overall Survival
8%
Surface Property
8%
Trogocytosis
8%
Cross Linking
7%
Medicine and Dentistry
T Cell
50%
Cancer Cell
41%
Malignant Neoplasm
37%
Programmed Cell Death
34%
Fusion Protein
33%
Neoplasm
31%
Antineoplastic Activity
29%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
23%
Cell Surface
22%
Phagocytosis
18%
Tumor Cell
16%
Cancer Immunotherapy
16%
Calreticulin
15%
Ovarian Cancer
15%
Rituximab
15%
Proteinase
15%
Cancer Therapy
13%
Bispecific Antibody
12%
Autoimmunity
12%
Macrophage
12%
Epidermal Growth Factor Receptor
11%
Diffuse Large B-Cell Lymphoma
11%
Cancer
10%
Target Cell
10%
Autophagy
10%
T Lymphocyte Receptor
10%
Acute Myeloid Leukemia
9%
In Vitro
9%
Cell Death
9%
CD20
9%
Chimeric Antigen Receptor
9%
Neutrophil
8%
Endoplasmic reticulum
8%
Tumor Immunity
7%
Cytotoxicity
7%
Chimeric Antigen Receptor T-Cell
7%
Nodular Melanoma
7%
Overall Survival
7%
Monoclonal Antibody
7%
Granulocyte
7%
Tumor Infiltrating Lymphocyte
7%
Leukemia Cell
7%
Antibody Dependent Cellular Cytotoxicity
7%
Adult T-Cell Leukemia/Lymphoma
6%
Lymphocyte
6%
Single Chain Fragment Variable Antibody
6%
Targeted Therapy
6%
Tumor Necrosis Factor
6%
Chimeric Protein
6%
8 Difluoromethoxy 1 Ethyl 6 Fluoro 1,4 Dihydro 7 [4 (2 Methoxyphenyl) 1 Piperazinyl] 4 Oxo 3 Quinolinecarboxylic Acid
6%
Keyphrases
Programmed Death-ligand 1 (PD-L1)
13%
Fusion Protein
12%
Luminescence
10%
In Vitro Screening
10%
Immunomodulatory
10%
Signaling Molecules
10%
Dual Signaling
10%
T Cell Receptor
9%
Immune Checkpoint Inhibitors
8%
Antigen-specific T Cell Response
8%
Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)
8%
Acute Myeloid Leukemia
8%
T Cells
7%
Antibody Fragment
6%
Acute Myeloid Leukemia Cells
6%
Human Leukocyte antigen-G (HLA-G)
6%
CD8+ T Cells
5%
Ligand-based
5%
Anticancer Immunity
5%
Acute T-cell Leukemia
5%
Chimeric Antigen Receptor T Cells (CAR-T)
5%
T-cell Malignancies
5%
Chimeric Antigen Receptor T-cell Therapy
5%
Targeted Cancer Immunotherapy
5%
Co-stimulatory Domain
5%
Autophagy
5%
Cancer Cell Death
5%
Endometrial Cancer
5%
Hepatic Ischemia-reperfusion Injury
5%
Programmed Cell Death Receptor Ligand 1
5%
Bifunctional Antibody
5%
Signal Regulatory Protein
5%
Intraepithelial T Cells
5%
Panel Block
5%
Apoptosis
5%
Vaterite
5%
Human Epidermal Growth Factor Receptor
5%
R-CHOP
5%
Apoptosis Induction
5%
4-1BB
5%
SFasL
5%
Leukemic T-cells
5%
Mismatch Repair
5%
Cytarabine Resistance
5%
Diffuse Large B-cell Lymphoma (DLBCL)
5%
KRAS mutant
5%
CD39
5%
Antibody Protein
5%
Peptidylarginine Deiminase 4
5%
Antigen Presentation
5%
